Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2004-08-20
2010-11-16
Landsman, Robert (Department: 1646)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C424S009300, C530S399000
Reexamination Certificate
active
07833964
ABSTRACT:
The present invention provides methods and compositions for reducing visceral fat by administering to the subject a therapeutically effective amount of a compound that increases the bioactive serum levels of insulin-like growth factor-I (IGF-I) in the subject, thereby ameliorating negative effects of visceral obesity. The invention is useful in the treatment, prevention, or amelioration of one or more symptoms of visceral obesity or IGF-I deficiency related condition, including, for example, cardiovascular disease and the metabolic syndrome.
REFERENCES:
patent: 4988675 (1991-01-01), Froesch et al.
patent: 5126324 (1992-06-01), Clark et al.
patent: 5579782 (1996-12-01), Masuo
patent: 5597797 (1997-01-01), Clark
patent: 6643542 (2003-11-01), Kawanishi
patent: 6846800 (2005-01-01), Johannsson et al.
patent: 7122515 (2006-10-01), Johannsson et al.
patent: WO91/18621 (1991-12-01), None
patent: WO94/09813 (1994-05-01), None
patent: WO9738709 (1997-10-01), None
Woods et al., J. Clin. Endocrin. Metab. 85: 1407-1411, 2000.
Min et al., Endocrin. 137: 1129-1137, 1996.
Clemmons et al., J. Clin. Endocr. Metab. 85:1518-1524, 2000.
Kunitomi et al., Int. J. Obesity 26: 361-369, 2002.
Moses et al., Diabetes, 45: 91-100, 1996.
Frayn, Brit. J. Nutrition, 83 (Suppl): S71-77, 2000.
Hong et al., J. Clin Endocr. Metab. 83: 4239-4245, 1998.
Gabriely et al., Diabetes, 51: 2951-2958, 2002.
Johannsson et al., J. Clin. Endocr. Metab. 82: 727-734, 1997.
Tulloch-Reid et al., Diabetes Care 26: 2556-2561, 2003.
American Diabetes Association (ADA), Diabetes Care, 22: 99-111, 1996.
Miller et al., Lancet 351: 871-875,1998.
Goodpaster et al., Diabetes 48: 839-847, 1999.
Arnhold et al., “Lack of reduction in body fat after treatment with insulin-like growth factor-I in two children with growth hormone gene deletions”, 2000, J Endocrinol Invest 23:258-262.
Bolinder et al., “Studies of acute effects of insulin-like growth factors I and II human fat cells”, 1987, Clin Endocrinol Metab, 65:732-737.
Carlsson et al., “Growth hormone and growth in diabetic rats: effects of insulin and insulin-like growth factor-I infusions”, 1989, J Endocrin 122:661-670.
Froesch et al., “Therapeutic potential of insulinlike growth factor I”, 1990, Trends Endocrinol Metab, 254-260.
Guler et al., “Short-term metabolic effects of recombinant human insulin like growth factor I in healthy adults”, 1987, N Engl J Med, 317:137-140.
Giacca et al., “Differential effects of IGF-I and insulin on glucoregulation and fat metabolism in depancreatized dogs”, 1990, Diabetes, 39:340-347.
Guevara-Aguirre et al., “Two-year treatment of growth hormone (GH) receptor deficiency with recombinant Insulin-like growth factor I in 22 children: comparison of two dosage levels and to GH- Deficiency”, 1997, J Clin Endocrinol Metab 82:629-633.
Grinspoon et al., “Effects of recombinant human insulin-like growth factor (IGR)-I and estrogen administration on IGF-I, IGF binding protein (IGFBP)-2, and IFGBP-3 in anorexia nervosa: a randomized-controlled study”, 2003, J Clin Endocrinol Metab 88: 1142-1149.
Isozaki O., “Interaction between leptin and growth hormone (GH) IGF-I axis”, Endocr J Mar. 1999;46 Suppl:S17-24.
Koutkia P., “Growth hormone-releasing hormone in HIV-infected men with lipodystrophy: a randomized trial”. JAMA Jul. 14, 2004;292(2):210-8.
Kunitomi M., “Relationship between reduced serum IGF-I levels and accumulation of visceral fat in Japanese men”, Int J Obes Relat Metab Disord. Mar. 2002;26(3):361-9.
Laron et al., “IGF-I treatment of adult patients with laron syndrome: preliminary results”, 1994, Clin Endocrinol 41:631-638.
Mauras et al., “Recombinant human insulin-like growth factor I has signification anabolic effects in adults with growth hormone receptor deficiency: studies on protein, glucose, and lipid metabolism”, 2000, J Clin Endcrinol Metab 85:3036-3042.
Svensson J. et al. “Effects of GH and insulin-like growth factor I on body composition”, J Endocrinol Invest Sep. 2003;26(9):823-31.
Zenobi et al., “Effects of insulin-like growth factor-I on glucose tolerance insulin levels, and insulin secretion”, 1992, J Clin Invest, 89:1908-1913.
Zapf et al., “Acute metabolic effects and half-lives of intravenously administered insulinlike growth factors I and II in normal and Hypophysectomized Rats”,1986, J Clin Invest, 77:1768-1755.
Zapf et al., “Insulin-like growth factors I and II: Some biological actions and receptor binding characteristics of two purified constituents of nonsuppressible insulin-like activity of human serum”, 1978, Eur J Biochem, 87:285-296.
Maccario et al. Effects of 36 hours fasting on GH/IGF-I axis and metabolic parameters in patients with simple obesity. Comparison with normal subjects and hypopituitary patients with severe GH deficiency. (2001) Int. J. Obesity 25:1233-1239.
Schoen et al. Lack of association between adipose tissue distribution and IGF-1 and IGFBP-3 in men and women. (2002) Cancer Epidemiology, Biomarkers and Prevention 11:581-586.
Nam et al. Effect of obesity on total and free insulin-like growth factor (IGF)-1, and their relationship to IGF-binding protein (BP)-1, IGFBP-2, IGFBP-3, insulin, and growth hormone. (1997) Int'l J. Obesity 21:355-359.
Nam, et al. Low-dose growth hormone treatment combined with diet restriction decreases insulin resistance by reducing visceral fat and increasing muscle mass in obese type 2 diabetic patients. Int J Obes Relat Metab Disord. Aug. 2001;25(8):1101-7.
Zvi Laron. Somatomedin-1 (recombinant insulin-like growth factor-1): clinical pharmacology and potential treatment of endocrine and metabolic disorders. BioDrugs. Jan. 1999;11(1):55-70.
Ross Clark. Recombinant human insulin-like growth factor I (IGF-I): risks and benefits of normalizing blood IGF-I concentrations. Horm Res. 2004;62 Suppl 1:93-100.
Johannsson et al. Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure. Journal of Clinical Endocrinology and Metabolism, 1997, vol. 82, No. 3, pp. 727-734.
Johannsson et al. Two years of growth hormone (GH) treatment increase isometric and isokinetic muscle strength in GH-deficient adults. Journal of Clinical Endocrinology and Metabolism, 1997, vol. 82, No. 9, pp. 2877-2884.
Johannsson et al. Growth hormone-deficient adults are insulin-resistant. Metabolism, 1995, vol. 44, No. 9, pp. 1126-1129.
Grundy, et al. Definition of metabolic syndrome- report of the national heart, lung, and blood institute/american heart association conference on scientific Issues related to definition. Circulation, Journal of the American heart association, 2004, vol. 109, pp. 433-439.
The IDF: Consensus worldwide definition of the metabolic syndrome. IDF promoting diabetes care, prevention and a cure worldwide. 2006, pp. 1-16.
Bjorntorp. Visceral obesity: a “civilization syndrome.” Obesity research. 1993, vo. 1, No. 4, pp. 206-222.
Reaven. Role of insulin resistance in human disease. Diabetes, 1988, vol. 37, pp. 1595-1607.
Fowelin, et al. Effects of treatment with recombinant human growth hormone on insulin sensitivity and glucose metabolism and adults with growth hormone deficiency. Metabolism, 1993, vol. 42, No. 11, pp. 1443-1447.
Richelsen, et al. Growth hormone treatment of obese woman for 5 wk: effect on body composition and adipose tissue LPL activity. Growth Hormone Effect on Body Composition in Obesity. 1994, pp. E211-E216.
Taaffe, et al. Recombinant human growth hormone, but not insulin-like growth factor-I, enhances central fat loss in postmenopausal women undergoing a diet and exercise program. Horm Metab Res, 2001, vol. 33, 156-162.
Thompson, et al. Effects of human growth hormone, insulin-like growth factor I, and diet and exercise on body composition of obese postmenopausal women. Journal of Clinical Endocrinology and Metabolism, 1998, vol. 83,
Borden Paula A.
Bozicevic Field & Francis LLP
Chandra Gyan
Landsman Robert
Tercica, Inc.
LandOfFree
Methods of reducing visceral fat by increasing levels of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of reducing visceral fat by increasing levels of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of reducing visceral fat by increasing levels of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4224857